Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Early treatment may improve outcomes in Shwachman-Diamond syndrome

More than 90% of children born with the rare bone marrow condition called Shwachman-Diamond Syndrome (SDS) survive beyond age 20. But fewer than 30% live beyond age 50.

23 Sep 2026

NCI awards $3.46 million grant to study resistance to acute myeloid leukemia treatment

A five-year, $3.46 million grant from the National Cancer Institute recently was awarded to The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and the University of California San Francisco (UCSF).

23 Sep 2026

City of Hope develops adaptive plug-and-play CAR T technology to attack tumors

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, have developed a new "plug-and-play" technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer.

22 Sep 2026

Daily vitamin C may benefit pre-cancerous blood disorder patients

Vitamin C is an essential nutrient that supports immune function, promotes wound healing and protects cells from molecular damage.

21 Sep 2026

New drug forces aggressive leukemia cells to die from stress

Pushing the accelerator and the brake at the same time is rarely a good idea. But researchers at the University of Gothenburg are using this approach to treat leukemia.

8 Sep 2026

Tumor environments sculpt diverse natural killer cells for cancer therapies

For decades, natural killer (NK) cells have been classified into two main groups based on surface markers: one specialized for cytokine production and the other for direct killing.

4 Sep 2026

Newly diagnosed AML patients benefit from less-intensive combination treatment

Investigators from the Mass General Brigham Cancer Institute have found that adults with newly diagnosed acute myeloid leukemia (AML) receiving a less-intensive combination of azacitidine and venetoclax had more than twice as much time before treatment failed, the leukemia returned or worsened, or they died, compared with patients receiving intensive chemotherapy.

2 Sep 2026

$15 million trial aims to improve treatment decisions for older AML patients

A newly funded national clinical trial initiative will gather critical evidence to determine the best treatment strategies for older adults with acute myeloid leukemia (AML), an aggressive, fast-moving blood cancer that leaves a substantial proportion of older patients facing uncertainty about whether to proceed to stem cell transplantation or continue non-transplant therapy.

27 Aug 2026

Protein degrader shows strong activity against treatment-resistant blood cancers

A first-in-class therapy to target MYC, one of the most sought-after and difficult targets in cancer biology, showed promise in hard-to-treat blood cancers, according to a new preclinical study from The University of Texas MD Anderson Cancer Center published in Blood.

24 Aug 2026

New study uncovers metabolic vulnerability in high-risk myelodysplastic syndromes

Researchers at the University of Colorado Anschutz Cancer Center have identified a previously unknown metabolic weakness in the stem cells that drive high-risk myelodysplastic syndromes (MDS), a discovery that could lead to more targeted treatments for this aggressive blood cancer.

10 Aug 2026

New gene signature predicts immunotherapy success for bone marrow cancers

A team led by researchers from the German Cancer Research Center (DKFZ), the HI-STEM Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital (UKHD) has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and, in principle, fight cancer cells, but is often not sufficiently activated.

10 Aug 2026

Researchers find a new genetic vulnerability in acute myeloid leukemia

A study published in Nature Cell Biology reports a new vulnerability in acute myeloid leukemia (AML) that might lead to novel therapies to treat this cancer while minimizing harm to normal cells.

7 Aug 2026

Experimental drug CS18 shows promise for overcoming cancer treatment resistance

Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts the ability of cancer cells to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 to treat human cancer in the future.

5 Aug 2026

New AI score enhances monitoring of myelodysplastic neoplasms

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.

20 Jul 2026

Researchers uncover new T cell attack mechanism against acute myeloid leukemia

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly sensitive to immune-based treatments and could guide the development of future cancer immunotherapies.

15 Jul 2026

New therapy targets Hippo pathway to fight treatment-resistant acute myeloid leukemia

Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy remained effective in treatment-resistant acute myeloid leukemia (AML) through activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance.

13 Jul 2026